Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP & General Mgr, Industrial | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,673 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 2,552 · Balance 21,673 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 12,376 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,376 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,129 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,129 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,164 | $746.42 | $868,832.88 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 14 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,208 F12 · price: Represents volume-weighted average price of sales of 1,164 shares of Company stock on November 23, 2022 at prices ranging from $746.26 to $746.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 256 | $745.56 | $190,863.36 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 13 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,372 F11 · price: Represents volume-weighted average price of sales of 256 shares of Company stock on November 23, 2022 at prices ranging from $745.07 to $745.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 780 | $744.56 | $580,756.80 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,628 F10 · price: Represents volume-weighted average price of sales of 780 shares of Company stock on November 23, 2022 at prices ranging from $744.42 to $744.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 101 | $743.66 | $75,109.66 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,408 F9 · price: Represents volume-weighted average price of sales of 101 shares of Company stock on November 23, 2022 at prices ranging from $743.24 to $743.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $742.58 | $73,515.42 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,509 F8 · price: Represents volume-weighted average price of sales of 99 shares of Company stock on November 23, 2022 at prices ranging from $742.56 to $742.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,002 | $741.34 | $742,822.68 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,608 F7 · price: Represents volume-weighted average price of sales of 1,002 shares of Company stock on November 23, 2022 at prices ranging from $741.00 to $741.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,808 | $740.29 | $1,338,444.32 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,610 F6 · price: Represents volume-weighted average price of sales of 1,808 shares of Company stock on November 23, 2022 at prices ranging from $740.00 to $740.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,124 | $739.48 | $2,310,135.52 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,418 F5 · price: Represents volume-weighted average price of sales of 3,124 shares of Company stock on November 23, 2022 at prices ranging from $739.00 to $739.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 944 | $738.57 | $697,210.08 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 F4 · price: Represents volume-weighted average price of sales of 944 shares of Company stock on November 23, 2022 at prices ranging from $738.07 to $738.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 373 | $737.37 | $275,039.01 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,486 F3 · price: Represents volume-weighted average price of sales of 373 shares of Company stock on November 23, 2022 at prices ranging from $737.01 to $737.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,005 | $736.46 | $740,142.30 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,859 F2 · price: Represents volume-weighted average price of sales of 1,005 shares of Company stock on November 23, 2022 at prices ranging from $736.00 to $736.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 686 | $735.57 | $504,601.02 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,864 F1 · price: Represents volume-weighted average price of sales of 686 shares of Company stock on November 23, 2022 at prices ranging from $735.11 to $735.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2022 at each separate price. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · derivative · entry 18 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 38,028 | $741.81 | $28,209,550.68 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,550 Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 18:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 50,000 | $378.98 | $18,949,000.00 |
DisclosureSEC source: 0001883850-22-000098 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 404 | $747.20 | $301,868.80 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,578 F5 · price: Represents volume-weighted average price of sales of 404 shares of Company stock on November 7, 2022 at prices ranging from $747.00 to $747.43. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2022 at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,782 | $746.56 | $2,076,929.92 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,982 F4 · price: Represents volume-weighted average price of sales of 2,782 shares of Company stock on November 7, 2022 at prices ranging from $746.15 to $746.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2022 at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,468 | $745.51 | $1,094,408.68 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,764 F3 · price: Represents volume-weighted average price of sales of 1,468 shares of Company stock on November 7, 2022 at prices ranging from $745.00 to $745.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2022 at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,032 | $744.61 | $1,513,047.52 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,232 F2 · price: Represents volume-weighted average price of sales of 2,032 shares of Company stock on November 7, 2022 at prices ranging from $744.02 to $744.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2022 at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,100 | $743.39 | $817,729.00 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,264 F1 · price: Represents volume-weighted average price of sales of 1,100 shares of Company stock on November 7, 2022 at prices ranging from $743.00 to $743.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 7, 2022 at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $742.79 | $74,279.00 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,364 Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · derivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 26,114 | $725.84 | $18,954,585.76 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,464 Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 34,000 | $381.92 | $12,985,280.00 |
DisclosureSEC source: 0001883850-22-000092 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 79 | $722.83 | $57,103.57 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 16 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,578 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 174 | $721.38 | $125,520.12 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 15 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,657 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 181 | $720.41 | $130,394.21 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 14 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,831 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 181 shares of Company stock on September 12, 2022 at prices ranging from $720.35 to $720.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 159 | $719.72 | $114,435.48 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 13 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,012 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 159 shares of Company stock on September 12, 2022 at prices ranging from $719.66 to $719.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 435 | $718.50 | $312,547.50 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,171 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 435 shares of Company stock on September 12, 2022 at prices ranging from $718.00 to $718.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 647 | $717.59 | $464,280.73 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,606 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 647 shares of Company stock on September 12, 2022 at prices ranging from $717.00 to $717.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,052 | $716.28 | $753,526.56 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,253 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 1,052 shares of Company stock on September 12, 2022 at prices ranging from $716.04 to $716.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 861 | $715.39 | $615,950.79 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,305 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 861 shares of Company stock on September 12, 2022 at prices ranging from $715.00 to $715.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 267 | $714.42 | $190,750.14 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,166 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 267 shares of Company stock on September 12, 2022 at prices ranging from $714.29 to $714.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 572 | $713.67 | $408,219.24 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,433 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 572 shares of Company stock on September 12, 2022 at prices ranging from $713.01 to $713.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 110 | $712.44 | $78,368.40 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,005 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 110 shares of Company stock on September 12, 2022 at prices ranging from $712.39 to $712.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 70 | $711.85 | $49,829.50 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,115 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 70 shares of Company stock on September 12, 2022 at prices ranging from $711.83 to $711.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $710.25 | $1,420.50 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,185 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 87 | $709.93 | $61,763.91 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,187 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 87 shares of Company stock on September 12, 2022 at prices ranging from $709.60 to $709.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 12, 2022 at each separate price. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · derivative · entry 18 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 35,304 | $730.96 | $25,805,811.84 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,274 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 40,000 | $555.67 | $22,226,800.00 |
DisclosureSEC source: 0001883850-22-000070 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,015 | $618.16 | $627,432.40 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 13 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,578 F11 · price: Represents volume-weighted average price of sales of 1,015 shares of Company stock on February 23, 2022 at prices ranging from $618.00 to $618.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,176 | $617.48 | $726,156.48 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,593 F10 · price: Represents volume-weighted average price of sales of 1,176 shares of Company stock on February 23, 2022 at prices ranging from $617.06 to $617.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 734 | $616.40 | $452,437.60 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,769 F9 · price: Represents volume-weighted average price of sales of 734 shares of Company stock on February 23, 2022 at prices ranging from $616.14 to $616.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $615.20 | $184,560.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,503 F8 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on February 23, 2022 at prices ranging from $615.03 to $615.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $614.53 | $368,718.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,803 F7 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on February 23, 2022 at prices ranging from $614.02 to $614.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $612.44 | $367,464.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,403 F6 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on February 23, 2022 at prices ranging from $612.03 to $612.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $611.65 | $489,320.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F5 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on February 23, 2022 at prices ranging from $611.30 to $611.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $610.41 | $122,082.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,803 F4 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on February 23, 2022 at prices ranging from $610.30 to $610.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $609.62 | $243,848.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,003 F3 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on February 23, 2022 at prices ranging from $609.59 to $609.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.